We are excited to offer a detailed white paper which describes how Lipopolysaccharide Binding Proteins (LBPs) are indicators of bacteria or bacterial products that may not be classified as sepsis.
This white paper describes how LBP is a 58-kD glycoprotein involved in the acute phase immunologic response to gram- negative bacterial infections. It binds with high affinity to the lipid A portion of lipopolysaccharide (LPS), which gram- negative bacteria express on their outer membrane. The presence of LBP in blood and bodily fluids is an indicator of bacterial infection, and as such is a useful marker of a number of disease states in humans, cows, mice and other animals.
Research on various chronic inflammatory conditions have positively correlated LBP levels with worsening disease states. This paper provides biotech researchers best practice guidelines to improve drug development procedures in pursuit of earlier stage treatments.
As a method of detecting this important acute phase protein, an ELISA (enzyme-linked immunosorbent assay) Kit from Cell Sciences is discussed in the white paper describing the specificity and reliable quantitation of the protein levels in samples such as blood, serum, lavage fluid, or milk. (The multispecies LBP ELISA kit maintains specificity for human LBP, while also providing flexibility to assess a broad range of LBP homologs in other species).
In addition to multispecies and mouse LBP ELISA Kits, Cell Sciences® offers their LBP monoclonal antibodies (that do or do not inhibit binding of LPS to membrane-bound CD14) which may be paired to act as controls in assays measuring LPS activation of CD14 expressing cells, as well. Other ELISA Kits available to be used in integrated research in this area, include recombinant human or mouse LBP proteins that have been shown to mediate binding of LPS to membrane-bound CD14. ELISAs are also available to measure human and mouse soluble CD14, and several CD14 monoclonal antibody clones and recombinant proteins that may be used to study binding of LPS to CD14. The white paper provides a broad baseline of best practices in establishing reliable procedural data on a variety of LBP-related subjects.